VHT241220C185000
- 0.00
- 0.000.00%
Vanguard Health Care ETF Newsroom
Wednesday Ends With Index Decline | Wall Street Today
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
Amgen Analyst Ratings
'Bunker' and 'Booster' Stocks in the U.S. – Which Would Perform Better in a Downturn Vs. Upturn?
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
UnitedHealth Group Analyst Ratings
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Ahead of Crucial Inflation Data
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Judge Denies Abbott Request for Retrial, Lower Damages in $500M Baby Formula Case
Amgen's weight loss drug has a remarkable 20% reduction effect, but with high side effects, causing the stock price to plummet by 12.3% at one point!
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Unpacking the Latest Options Trading Trends in Intuitive Surgical
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.
Intuitive Surgical Analyst Ratings
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce